C12N 2760/20121
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2760/20121 (Viruses as such) appears on 4 US grants and 13 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 13
- Assignees
- 7
- Inventors
- 27
- Latest grant
- 22 Oct 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 0 | 2 |
| 2012 | 1 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 2 |
| 2023 | 0 | 3 |
By publication year.
Recent patents
- Human antibodies against rabies and uses thereof22 Oct 2019US 10,450,367 B2University of Massachusetts
- Pan-lyssavirus vaccines against rabies2 Feb 2016US 9,248,179 B2The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
- Attenuated live triple G protein recombinant rabies virus vaccine for pre- and post-exposure prophylaxis of rabies9 Oct 2012US 8,282,939 B2Thomas Jefferson University
- Recombinant rabies virus compositions13 Apr 2010US 7,695,724 B2Thomas Jefferson University
- Viral guide rna delivery31 Aug 2023US 2023/0270840 A1
- Coronavirus vaccine compositions and methods of use22 Jun 2023US 2023/0190919 A1Thomas Jefferson University
- Chimpanzee adenovirus constructs with lyssavirus antigens25 May 2023US 2023/0158134 A1Glaxosmithkline Biologicals SA
- Novel lyssa virus phosphoproteins9 Jun 2022US 2022/0177525 A1
- Chimpanzee adenovirus constructs with lyssavirus antigens14 Apr 2022US 2022/0112245 A2Glaxosmithkline Biologicals SA
Most cited
By later US patents